Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987608 | 0.85 | CES1 (0.40) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL459641 | 0.85 | CES1 (0.40) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL10001805 | 0.84 | CYP11B2 (0.43) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL26785982 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL26786011 | 0.81 | CYP11B2 (0.42) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL5119030 | 0.80 | CYP3A4 (0.42) | CYP11B2CYP3A4CYP17A1CYP11B1MAPK1 | |
| SCHEMBL16340167 | 0.79 | NPC1 (0.42) | CYP11B2CYP3A4CYP17A1CYP11B1CYP19A1 | |
| SCHEMBL13384396 | 0.79 | CYP3A4 (0.41) | CYP11B2CYP3A4CYP17A1CYP11B1NPC1 | |
| SCHEMBL6789105 | 0.75 | PTPN1 (0.46) | CYP3A4PKMMAPK1NPC1RAB9A | |
| SCHEMBL7077942 | 0.75 | TDP1 (0.41) | CYP11B2CYP3A4CYP17A1CYP11B1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| CN-1854134-B | Piperazine compounds, their preparation method and pharmaceutical composition containing same | SERVIER LAB | 2010-04-21 | — | — | CN | disclosed |
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| CN-1854134-A | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2006-11-01 | — | — | CN | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106241-A1 | PIPERAZINE DERIVATIVES AND USE THEREOF AS SEROTONIN REUPTAKE INHIBITORS OR AS NEUROKININ ANTAGONISTS | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | WO | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CYP11B2 276/4885CYP3A4 462/4885CYP17A1 796/4885 |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | HLCS, NCL, NUDC | CYP11B2 790/4885CYP3A4 1126/4885CYP17A1 2285/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CYP11B2 276/4885CYP3A4 462/4885CYP17A1 796/4885 |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | HLCS, NCL, NUDC | CYP11B2 1076/4885CYP3A4 1368/4885CYP17A1 3062/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | CYP11B2 276/4885CYP3A4 462/4885CYP17A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.